For many years, CLL has ‘reigned’ with the title of ‘most common leukemia in the Western world.’ That title may be in jeapordy, though, if recent trends continue. Already some say that the title has already fallen to another contender. What is this mystery leukemia that seemingly has come out of nowhere to grab the crown? Myelodysplastic syndrome, or MDS.
Perusing the ASH abstracts, a number of papers caught my eye, including this one: http://ash.confex.com/ash/2009/webprogram/Paper19496.html. The authors say that “Myelodysplastic syndromes (MDS) are becoming the most commonly diagnosed forms of leukemia in the US .” Also, consider this very interesting paper that asserts that MDS may be afflicting over a hundred thousand Americans: http://www.moffitt.org/CCJRoot/v16s4/pdf/2.pdf
One reason MDS might be increasing in frequency is that it can arise as a result of chemotherapy for other cancers, including fludarabine-containing regimes such as FCR for CLL. As cancer patients live longer (always a good thing, of course) other cancers will make their presence known, unfortunately.
Doing Great Two Years on CLL Epcoritamab Trial: Time to Stop?
-
August 2025 marks two years on the epcoritamab trial for my CLL. Since Feb
2024, blood tests show zero to one cancer cell per million white blood
cells....
5 days ago
No comments:
Post a Comment